SHORT INTRO VIDEO
Explore DRISTi (Diabetic Retinopathy Intelligent Screening Technology integrated)—our advanced tool for diabetic retinopathy screening. Powered by AI, it operates offline, ensuring accurate, accessible eye care anywhere. Watch our brief video to see how DRISTi supports healthcare providers with state-of-the-art technology in minutes. Step into the future of medical diagnostics.
Using State of the Art Transformers Architecture
DRISTi harnesses the power of advanced AI algorithms to deliver unparalleled precision in retinal pathology detection. By accurately identifying and classifying four distinct levels of Diabetic Retinopathy (stages 0-4), DRISTi provides precise and reliable assessments, supported by explainable AI. This ensures that healthcare providers can understand and trust the AI's decision-making process.Beyond Diabetic Retinopathy, DRISTi's capabilities extend to the identification of 16 DR-related pathologies. This comprehensive detection includes various retinal abnormalities associated with diabetes, enabling early intervention and tailored treatment plans for patients. Moreover, DRISTi's sophisticated algorithms can detect 20 additional multi-pathologies, covering a wide range of retinal conditions like ARMD, Glaucoma and more. This broad detection spectrum ensures a thorough retinal health check-up, which is crucial for the early identification and management of various eye diseases. By integrating such extensive detection capabilities, DRISTi plays a vital role in facilitating early intervention, improving patient outcomes, and enhancing the overall quality of eye care.
Glaucoma Detection
DRISTi is engineered for versatility and adaptability, making it an invaluable tool in diverse and challenging environments. One of its standout features is the ability to operate independently, without the need for an internet connection. This offline functionality is made possible by an integrated Compute Stick, ensuring that DRISTi delivers reliable performance even in remote or resource-limited settings. This independence from internet connectivity significantly enhances accessibility, allowing advanced diabetic retinopathy screening tools to reach underserved areas. Healthcare providers can confidently use DRISTi in rural clinics, mobile health units, and other remote locations, ensuring that patients receive critical eye care regardless of their geographic location. In addition to its robust diabetic retinopathy screening capabilities, DRISTi is also equipped to predict the Cup To Disc Ratio (CDR). This crucial measurement helps in the early detection of Glaucoma suspects, facilitating timely interventions that can prevent vision loss. By providing comprehensive eye health assessments in offline mode, DRISTi empowers healthcare professionals to deliver high-quality care and improve patient outcomes in any setting.
DRISTi is an offline AI retina screening device for fast, accessible diabetic retinopathy screening at the point of care.
DRISTi combines a non-mydriatic fundus camera with on-device AI. It captures retinal images and produces a rapid screening report that can identify four levels of diabetic retinopathy and diabetic macular edema, while explainable AI highlights areas of interest for clinical review.
DRISTi is built for ophthalmologists, eye hospitals, clinics, NGOs, mobile health units, and screening camps. Its portable workflow supports diabetic retinopathy screening in both established facilities and remote areas across India.
DRISTi is a screening and clinical decision-support tool, not a replacement for a qualified clinician's diagnosis. Artelus reports training on more than 100,000 retinal images. DRISTi is listed as CE Class I (MDD), and CE Class II B (MDR) is under review. Request the latest validation and regulatory documentation for your intended deployment.
An integrated compute stick lets DRISTi analyze images and generate reports without an internet connection. This offline design is useful for rural clinics, mobile screening units, and areas with limited connectivity, while helping keep patient data on site.
DRISTi pricing is quote-based and depends on the camera configuration, deployment scale, training, support, and location. Contact Artelus for a product demonstration and a quotation tailored to your clinic, hospital, NGO, or screening program.
DRISTi analyzes retinal images to support screening across four levels of diabetic retinopathy and diabetic macular edema. Results should be reviewed within the appropriate clinical workflow and do not replace diagnosis by a qualified eye-care professional. Ask Artelus for current validation results for your intended use.
DRISTi is identified as CE Class I (MDD), with CE Class II B (MDR) under review. Regulatory status and deployment requirements can differ by country and use case, so confirm the current documentation with Artelus before purchase.
A typical setup includes the DRISTi fundus camera, integrated compute stick, power supply, and operator onboarding. The system is designed for non-mydriatic, point-of-care screening and does not require continuous internet access. Artelus can confirm site, training, maintenance, and integration requirements.
Yes. DRISTi is designed to capture, analyze, and report on retinal images locally, without relying on a continuous cloud or internet connection. This supports screening in rural clinics, mobile units, and outreach programs with limited connectivity.
Evidence and recognition
Review the sources behind Artelus product and performance claims. Product results can vary by device, dataset, population, and clinical workflow; DRISTi and OCT AI are intended to support qualified healthcare professionals.
Artelus identifies DRISTi as CE Class I (MDD), with CE Class II B (MDR) under review. The Products page explains the manufacturer's declaration of conformity; request the current certificate and regulatory documentation directly from Artelus.
View certification informationA 96% sensitivity result is reported in Artelus's interview coverage about validation with the Dubai Health Authority. This is a reported historical result, not a universal accuracy guarantee or a substitute for current validation evidence.
Read the validation referenceExplore independent coverage of Artelus's diabetic retinopathy screening work, including reporting on the Dubai Diabetes Hospital results and the company's healthcare mission.
The foundational ethos of Artelus is encapsulated in its forward-thinking vision: Leveraging state-of-the-art Deep Learning architectures to democratize healthcare for the "Forgotten Billions". At Artelus.ai, we are dedicated to advancing eye care through innovative technology and comprehensive solutions, making high-quality diagnostics accessible to all. Join us in revolutionizing healthcare and improving the lives of millions around the world.